Tolero Pharmaceuticals Opens New Headquarters in Lehi
Company leaders gather with local dignitaries to inaugurate facility
SALT LAKE CITY, November 10, 2017 -- Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing treatments for hematological diseases, today unveiled its new headquarters at 3900 North Traverse Blvd in Lehi, Utah. To inaugurate the facility, Chief Executive Officer and Founder David J. Bearss, Ph.D. will be joined by leadership from Tolero’s parent company, Sumitomo Dainippon Pharma Co., Ltd., representatives from the Leukemia and Lymphoma Society, and dignitaries from state and local governments for a ribbon-cutting ceremony at 10:00 a.m. local time.
"On behalf of all our employees, I am pleased to be a corporate citizen of Lehi and proud to call Utah our home," said Dr. Bearss. "Opening a new headquarters and cutting-edge research facility underscores Tolero’s commitment to science that may make a difference in the lives of cancer patients across the country, in the state of Utah, and here in our own backyard."
Tolero has been headquartered in Lehi since its inception in 2011. Tolero’s new facility includes a research laboratory where the company will continue to advance its pipeline of potential treatments for acute myeloid leukemia, and other cancers.
About Tolero Pharmaceuticals, Inc.
Tolero is a clinical-stage biopharmaceutical company researching and developing treatments to improve and extend the lives of patients with oncological and hematological diseases. Our diverse pipeline targets important biological drivers of blood disorders to treat leukemias, anemia, and solid tumors, as well as targets of drug resistance and transcriptional control. Tolero is based in the United States and is a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., a pharmaceutical company based in Japan. Additional information about the company and its product pipeline can be found at www.toleropharma.com.
Tolero Forward-Looking Statements
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Tolero's business. Tolero undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.